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Desferrioxamine (DFO), deferiprone (L1) and desferasirox (ICL-670) are clinically approved iron chelators used to
treat secondary iron overload. Although iron chelators have been utilized since the 1960s and there has been much
improvement in available therapy, there is still the need for new drug candidates due to limited long-term efficacy
and drug toxicity. Moreover, all currently approved iron chelators are of low molecular weight (MW) (<600 Da) and
the objectives reported for the “ideal” chelator of low MW, including possessing the ability to promote iron excretion
without causing toxic side effects, has proven difficult to realize in practice. With prolonged iron chelator use, patients
may develop toxicities or become insensitive. In contrast, the limited research that has been geared towards developing
higher MW, polymeric, long circulating iron chelators has shown promise. The inherent potential of polymeric iron
chelators toward longer plasma half-lives and reduction in toxicity provides optimism and may be a significant addition
to the currently available low MW iron chelators. This article reviews knowledge pertaining to this theme, highlights
some unique advantages that these nanomedicines have in treating systemic iron overload as well as their potential
utility in the treatment of other disease states.
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Iron
Iron is essential for oxygen transport, DNA synthesis
and energy metabolism [1]. Thus, it is life sustaining in
virtually all living organisms. The usefulness of iron re-
sults from its ability to cycle between its ferrous (Fe2+)
and ferric (Fe3+) forms in oxidation and reduction reac-
tions [1,2]. Although iron is abundant in the earth’s
crust, Fe2+ is highly toxic, while Fe3+ is insoluble in
aqueous solution at physiological pH, rendering it in-
accessible. As a result, obtaining bioavailable iron is a
continual challenge which living organisms have over-
come by evolving to conserve iron [1-3]. Organisms have
acquired highly organized mechanisms of iron acqui-
sition, transport and storage; microorganisms use low
molecular weight (MW) high affinity iron ligands or
siderophores, while more complex life forms like mam-
mals use specialized storage and transport proteins [3].* Correspondence: jay@pathology.ubc.ca
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article, unless otherwise stated.Under normal physiological conditions, the human
body contains 3.5-5 g of iron, with the majority (over
70%) existing as hemoglobin [3]. The remainder is found
in myoglobin, intracellular storage iron in the hepato-
cytes of the liver, spleen and bone marrow macrophages,
and in proteins and enzymes that are involved in cellular
respiration [1-3].
Iron metabolism is highly conservative in man, with
the efficient recycling of hemoglobin iron forming the
major component of iron regulation. Intestinal iron up-
take also plays a key role in maintaining human iron
homeostasis; 1–2 mg of dietary iron is absorbed daily
and approximately 1–2 mg of iron is lost daily due to
the sloughing off of epithelial cells, secretions from the
skin and gut, and small losses of blood from the gastro-
intestinal tract [2,3]. This indicates the conservative na-
ture of iron metabolism and recycling. The process of
iron recycling and metabolism is schematically demon-
strated in Figure 1.
Under normal physiological conditions, iron is com-
plexed with proteins like transferrin (Tf) or other iron
binding proteins which ensure that it is unable to causeBioMed Central. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Iron recycling and distribution in the body. Body iron is primarily located in erythrocytes (>70%) which are efficiently recycled by
macrophages of the liver and spleen. Enterocytes obtain iron from the diet. Macrophages, which obtain iron from the phagocytosis of senescent
RBCs release iron into the circulation where it binds to plasma transferrin, the iron transport protein. Transferrin delivers iron to the erythron of
the bone marrow and to other sites like hepatocytes of the liver, the main iron storage site in the body. There is no physiological excretion
pathway for iron.
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ported by Tf and is unavailable for redox activity. Tf has
a high iron binding capacity which prohibits the accu-
mulation of toxic unshielded or non-transferrin bound
iron (NTBI). Tf contains 2–3 mg of iron and is hypo sat-
urated at ~30% under normal physiological conditions.
Tf delivers iron to hepatocytes and specific binding sites
on red cell precursors of the bone marrow involved in
the synthesis of hemoglobin. Tf also captures iron re-
leased into the plasma from intestinal enterocytes or
cells which catabolize senescent RBCs [4,5].
Within cells, ferritin is the major storage molecule for
reusable iron and accounts for ~27% (1 g) of the total
body iron in normal individuals [6]. Ferritin has a stor-
age capacity of 4500 atoms of iron per ferritin molecule
and iron storage in ferritin ensures that iron is stored
within cells in a safe redox inactive form. Therefore, fer-
ritin reduces the toxicity from free radical generationwhile ensuring that iron is also available for mobilization
for metabolic processes. Ferritin also helps to re-establish
normal redox conditions during oxidative stress by remov-
ing ferrous ions and oxygen from the cytoplasm. Under
pathological conditions in which ‘iron overload’ occur, ex-
cess iron is deposited as insoluble ‘iron cores’ of partially
degraded ferritin or hemosiderin, primarily in liver, spleen,
endocrine organs and myocardium of the heart [1,2].
Although electron shuttling is vital in metabolic pro-
cesses, under conditions of excess, iron may catalyze harm-
ful reactions that generate free radicals which amplify the
development of reactive oxygen species (Figure 2) [7]. This
may occur via the Haber-Weiss reaction in which hydro-
gen peroxide (H2O2) reacts with the superoxide radical
(O2) to produce the hydroxyl radical (OH·), the most react-
ive radical in the body [7]. Although this reaction occurs at
minimal levels under normal physiological conditions, it
can be catalyzed by iron, leading to accumulation of free
Figure 2 Harmful redox cycling of iron. Iron (Fe) can participate in one electron oxidation and reduction reactions. This leads to the generation of
harmful free radicals in the presence of oxygen. The hydroxide radical and hydroxide anion (OH−) are produced when hydrogen peroxide reacts with
ferrous iron. Ferric iron is in turn reduced by the superoxide radical (O2·-). Redox active or “labile” iron reacts with cellular hydrogen peroxide (H2O2)
producing the hydroxyl radical (OH·), which perpetuates free radical production, ultimately increasing cellular reactive oxygen species generation. The
resulting oxidative stress is associated with damage to cellular components and organs [7].
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and disturb metabolic functions [7]. It has been shown
that the increased generation of free radicals can oxidize
lipids, proteins, and DNA in major organs with the heart
being most susceptible. Thus, the disruption of normal
cellular redox equilibrium is possible with very small
amounts of misplaced iron, and the magnitude of the body
iron burden is the most important determinant of the en-
suing organ damage.
Transfusion associated iron overload
In contrast to the highly evolved methods of iron acquisi-
tion, storage and transport mechanisms, the ability to off-
load excess iron remains challenging as there is no known
physiological pathway to actively excrete iron. This is the
major challenge in disease states like β-thalassemia (β-TM),
sickle cell disease (SCD) and myelodysplastic syndromes
(MDS) that invariably lead to iron overload [1-3,8,9].
Red blood cell (RBC) transfusions are used to ameliorate
anemia in patients with β-TM and MDS and can prevent
vaso-occlusive events in SCD [8,9]. Patients with these dis-
orders develop severe anemia due to ineffective erythropoi-
esis and hemolysis, which causes large numbers of marrow
erythrocyte precursors to undergo apoptosis before matur-
ity into erythrocytes. This leads to severe anemia. In the
case of SCD, there is the added risk of stroke due to the
lack of deformability and enhanced stickiness of RBCs
which may cause the obstructive adhesion of sickled cells
to each other and the vasculature [9].
Further, ineffective erythropoiesis results in a drastic
increase in plasma iron turnover, with the turnover of
plasma iron occurring at a rate that is 10–15 times
greater than in patients with normal erythropoiesis [10].
As a result, patients can accumulate over 2.5 g of iron
annually from this process, which results in a “primary”
iron overload state. In addition to this inherent iron ac-
cumulation, patients receive red blood cell transfusionsfrequently, which, although highly beneficial in suppress-
ing erythropoiesis and anemia, put patients at risk of
developing “secondary” or transfusion associated iron
overload.
Each unit of RBC contains approximately 250 mg of
iron [8]. Since humans lack an iron excretion pathway,
chronically transfused patients accumulate excess iron at
a rate of 0.2-0.4 mg/kg/day if transfused more than twice
per year [8,10]. This excess iron accumulation causes a
saturation of the body’s iron regulatory mechanisms and
a subsequent disruption of normal iron regulation.
As the iron loading from transfusions increase, trans-
ferrin in the plasma becomes saturated and NTBI appears
in the serum [11]. This toxic pool of partially ligated iron
accumulates in plasma and is subsequently, and in some
cases, preferentially taken up by cells. For example, the
rate of NTBI uptake by cultured rat heart cells is greater
than 300 times that of transferrin bound iron [10]. As this
toxic pool of NTBI accumulates, an intracellular labile
iron pool (LIP) is formed and ultimately facilitates harmful
redox damage to tissues through the formation of the free
hydroxyl radical.
The excess iron is accumulated primarily in the liver,
spleen, endocrine organs and myocardium. The cytosolic
LIP mirrors the cellular iron content and its fluctuations
are considered to trigger homeostatic adaptive responses.
Once homeostatic mechanisms become saturated, excess
iron can ultimately lead to organ dysfunction and death if
left untreated [8,10,12]. Figure 3 shows some of the poten-
tial effects of iron overload on major organs.
Iron chelation therapy: treatment of transfusion
associated iron overload
Iron chelation therapy is clinically indicated for the treat-
ment of transfusion dependent patients with β-TM, SCD
and MDS [8,10,13,14]. Iron chelation therapy involves the
use of molecules which can bind iron under physiological
Figure 3 Excess labile iron causes damage to the body’s organ systems. Chronic transfusion therapy results in the saturation of serum transferrin
and the development of toxic iron pools in cells and tissues. NTBI in the plasma and labile cellular iron (LCI) react with cellular membranes and
organelles, causing peroxidation, DNA damage and protein dysfunction. The liver, heart, pancreas and other endocrine organs are most commonly
damaged. These events ultimately lead to organ dysfunction, failure and death if left untreated.
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“chelate” which is subsequently excreted via the feces and/
urine, enabling safer body iron levels. Iron chelation ther-
apy protects cells against oxidative damage by reducing the
pool of reactive iron in the plasma and cytosolic LIP in
cells. Iron chelation therapy inhibits the lipid peroxidation,
protein oxidation and cellular damage that accompanies
iron overload [15,16]. ICT is recommended after receiving
10–20 transfusions of erythrocytes in order to prevent se-
vere iron loading and damage in major organs [8,10]. Cur-
rently, three iron chelators are approved for treating
transfusion associated iron overload (Figure 4).Desferrioxamine
The most thoroughly characterized iron chelating drug is
desferrioxamine (Desferal®, DFO) which has been the
standard of therapy for over 40 years. Used since the
1960s, DFO has demonstrated efficacy in prolonging life
and improving quality of life for transfusion dependent
thalassemic patients (8,13,17). DFO has demonstrated effi-
cacy at preventing lipid peroxidation which leads to organ
damage, promoting iron excretion, arresting fibrosis, sig-
nificantly decreasing deaths by cardiac disease reducing
hepatic iron concentrations and extending lifespan in iron
overloaded patients [12-14,16,17].DFO is a high affinity iron (III) chelator with a log sta-
bility constant of 30 for the Fe(III) complex and a mo-
lecular weight of 560 Da. Due to its hexadentate nature,
DFO binds iron in a 1:1 ratio producing a stable com-
plex that prevents iron from producing harmful free rad-
icals [18]. DFO can access iron by two methods; directly
interacting with hepatocellular iron and subsequent bil-
iary excretion, as well as from the destruction of RBCs
in the reticuloendothelial cells (RES), directly or follow-
ing its release into plasma as NTBI [8,10]. DFO enters
the liver via active transport and interacts with liver and
extracellular iron. This leads to excretion primarily by
urine as well as some biliary iron excretion [10]. The
DFO–Fe(III) complex (Figure 4) does not redox-cycle
and this reduces the chances of iron redistribution and
toxicity within the body [18].
DFO therapy improves lifespan and quality of life
[13,14,17]. Borgna-Pignatti et al. showed that mortality
at 20 years of age had fallen significantly after the advent
of DFO chelation; diabetes had fallen from 15.5% in
those born between 1970-74 when DFO therapy was
relatively new, to 0.8% in those born after 1980, when
DFO was more frequently prescribed [17]. This strongly
supports the idea that the age at which transfusion
dependent patients begins DFO therapy, as well as ad-
herence to therapy may modulate risk of heart disease
Figure 4 The chemical structure of clinically approved iron chelators and their iron (III) complexes.
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shown the benefit of iron chelation with DFO in prolong-
ing life, significantly reducing the incidence of cardiac
disease, liver failure and other endocrine disorders in
compliant patients [13].
Despite these advantages, DFO is hardly the “ideal”
chelator. Due to its low lipophilicity and high MW (560
Da), DFO is not readily absorbed by gastrointestinal
cells. In addition, it has a very short circulation half-life
of ~20 minutes in humans and must be subcutaneously
infused at doses of 40–60 mg/kg for 8–12 h a day, 5–7
days per week. Additionally, DFO at high doses has been
associated with severe neurotoxicity, causing sensori-
neural hearing loss, visual electroretinographic distur-
bances, and impaired growth and bone development
[19-21]. Thus, the use of DFO has been hindered by its
shortcomings and attempts toward generating more effi-
cient iron chelators have continued.
Deferiprone
Deferiprone (Ferriprox®, Cipla, L1) is the second chelator
to receive approval for the treatment of iron overload. It
was first reported as a potential orally active iron chela-
tor and efficient at in vivo iron removal in 1987 and was
subsequently licensed for use in India in 1994 and Europe
in 1999 with special conditions [22-24]. Due to questions
regarding safety and chelation efficiency, L1 only received
full marketing authorization in Europe in 2002 and by the
FDA in 2011.
L1 is a bidentate chelator thus, 3 L1 molecules are
needed to chelate one atom of iron [22,23]. As a result,
the efficacy of L1 as an iron chelator is highly dependenton the concentration ratio of chelator and iron in the en-
vironment. At low L1 to iron concentrations, L1 may bind
to iron incompletely. These partially bound forms of iron
with unoccupied coordination sites may accumulate and
remain reactive. Furthermore, these partially chelated
forms of iron are able to catalyze the formation of harmful
radicals and other reactive oxygen species [23].
In the first study reporting its efficacy, L1 was shown to
cause iron excretion at a rate proportional to the iron load
of the patients and the dose given in the 4 MDS and 4 β-
thalassemia major patients participating in the study [22].
Further, the iron excretion levels in urine were found to
be similar to that obtained with therapeutic doses of DFO.
Rombos et al. reported that L1 was safe and caused a re-
duction in iron overload in Greek thalassemics without
causing considerable side effects [24].
However, several subsequent studies have shown that
L1 therapy alone may be ineffective in ensuring negative
iron balance in many patients, especially in patients with
less severe iron loading [25-28]. Hoffbrand et al. found
no significant reduction in urinary iron excretion in any
of the patients enrolled in the study and no significant
change in the serum ferritin levels of more than half of
the patients that received L1 treatment for more than 3
years [28]. While Cohen et al. found that L1 can reduce
and maintain body iron in some but not all patients; L1
did not reduce body iron overload to a level below that
achieved by DFO in those patients that had lower base-
line iron levels [26]. This demonstrates that the daily L1
dose of 75 mg/kg body weight/day induces less iron ex-
cretion than the standard daily dose of DFO 50 mg/kg
body weight/day.
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in some but not all patients and that the effects of pro-
longed therapy were not sustained [27]. In addition, al-
though L1 can mobilize iron intracellularly and has been
shown to reduce cardiac iron it is unable to promote ad-
equate iron removal and prevent death by cardiac disease
in some patients. This was well described in a review by
Hoffbrand et al. For example, it was reported that 9 out of
532 thalassemic patients undergoing consistent L1 treat-
ment for 3 years died of heart failure [25]. In addition,
Hoffbrand et al. found that out of 51 L1-treated patients,
4 out of the 5 patient deaths were caused by cardiac dys-
function [28]. This indicates that in some patients with
myocardial iron overload and continuing need for blood
transfusions, L1 was not reliable at preventing further iron
loading [28].
One of the major reasons for the limited efficacy of L1
in clinical use is its rapid metabolism in the liver. The 3-
hydroxyl functional group that is found on the L1 mol-
ecule is required for effective iron chelation. However,
this is also the site of rapid metabolism by glucoronida-
tion in liver cells [18,25,27]. Studies which measured L1
recovery in the urine found that over 85% of the L1 dose
given to patients may be recovered in the urine as the
inactive 3-O-glucuronide conjugate [18,25].
In addition to the challenging metabolism of L1 de-
scribed above, severe side effects of L1 can also be limiting
without adequate monitoring of patients. Agranulocytosis
is considered to be the most serious side effect of L1 use
[8,10,26-28]. Milder neutropenia is also common, occur-
ring in up to 4.8% of patients in some studies [25]. Thus,
it is necessary to carefully monitor blood counts, espe-
cially in patients that are given higher doses. Arthralgia,
nausea, gastrointestinal symptoms, zinc deficiency and
fluctuating liver enzymes have also been reported [25-28].
Desferasirox
Desferasirox (Exjade®, ICL-670) is the second orally ac-
tive iron chelator and the most recent to become ap-
proved for the treatment of transfusion associated iron
overload [29-32]. It has a MW of 373 Da. Although tri-
dentate, that is, requiring 2 molecules to bind each iron
atom, ICL-670 has been shown to be highly selective for
iron without promoting the excretion of other metals
like zinc and copper [29]. Studies in rats and humans
demonstrate that ICL-670 possesses a half-life of 8–16
h, which allows ICL-670 plasma levels to be sustained at
a therapeutic range for longer than either DFO or L1.
Subsequent clinical studies have confirmed the iron che-
lation efficacy of ICL-670.
ICL-670 has been reported to be significantly more ef-
ficient than DFO and L1 at promoting iron excretion. At
equal molar concentrations ICL-670 is reported to be
five times more efficient than DFO and ten times moreeffective than L1 [29]. Several studies show a linear
dose-dependent increase in the amount of iron excretion
by iron overloaded patients and the doses of ICL-670
given. ICL-670 was reported to induce iron excretion in
a manner that would likely prevent iron accumulation in
most patients requiring standard transfusion therapy for
iron overload [30,31].
Like L1, ICL-670 is highly cell permeable. Moreover, it
is absorbed by some cells more rapidly than L1 [32]. The
active molecule is highly lipophilic and cell permeable
in vivo and feces is the main route of excretion for ICL-
670 and its metabolites. Renal excretion accounts for ap-
proximately 8% [30,31]. Unlike L1, which is absorbed but
rapidly inactivated through metabolism, ICL670 rapidly
increases in concentration in the plasma of patients and
persists at detectable levels for several hours.
Although the long half-life and iron removal efficacy of
ICL-670 allows once-daily dosing and offers significant
improvement in convenience for patients when compared
to DFO and L1, the toxicities reported to accompany pro-
longed ICL-670 use should be considered [33-37]. In early
studies, changes to the renal tubular epithelium were ob-
served as side effects of ICL-670 use [33]. Subsequent
studies have confirmed that renal toxicity, hepatic dys-
function and thrombocytopenia are the main concerns for
patients undergoing iron chelation therapy with ICL-670.
Reports indicate that prolonged use can cause Fanconi
syndrome [33-35]. Additionally, a mild, dose-dependent
increase in serum creatinine occurs in some patients.
Thus, ICL-670 use requires meticulous monitoring of kid-
ney, liver, and hematopoietic function.
In a recent report by Kontoghiorghes, the fatalities asso-
ciated with ICL-670 use are described to be the highest
among the clinically approved chelators. When compared
to DFO and L1 which have been in use for much longer
periods, the toxicity due to chelation with ICL-670 is high
[37]. More importantly, according to this report, ICL-670
was listed as the drug associated with the second highest
number of deaths in 2009. Kontoghiorghes, reported that
there is a steady increase in the ICL-670 induced deaths in
patients per year and that most are caused in elderly pa-
tients with MDS. Although the evidence presented in this
report was questioned by Riva, the potential seriousness of
ICL-670 induced toxicity should not be overlooked [38].Continuous advances toward the development of
improved iron chelators
The shortcomings of DFO, L1 and ICL-670 highlight the
need for improved chelation therapy. Challenges such as
the inefficiency of DFO and necessity for continuous
subcutaneous infusion; the toxicities of L1 and its inabil-
ity to adequately control body iron levels with prolonged
use; and the severe toxicities associated with ICL-670,
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better options for iron chelation.
Fe(III) selective chelators are the most fitting for bio-
logical applications because they are less likely to deplete
other essential metals, which are commonly divalent.
However, because the size of a drug influences intestinal
absorption, creating orally active hexadentate chelators
has proven difficult [39]. Instead, the greatest emphases
have been placed on generating novel bi and tridentate
chelators or modifying the properties of existing ligands.
Over the years, several promising agents which vary in
denticity, metal selectivity for Fe(III), toxicity, stability of
the Fe-chelator complex and lipophilicity have been pro-
posed and tested in several in vivo models including ro-
dents, marmosets, dogs, and primates, with promising
agents progressing to clinical trials [40-43]. Figure 5
shows the structures of a few previously reported iron
chelators with potential clinical utility.
HBED
N, N’-bis (2-hydroxybenzyl) ethylenediamine-N-N’-diace-
tic acid (HBED) is a hexadentate, phenolic aminocarboxy-
late (MW 388) which has been tested for utility as an iron
chelating agent (Figure 5). HBED has a high affinity and
specificity for Fe(III) and like DFO, renders it virtually
inert and incapable of forming harmful radicals which
damage cellular components and organs [40]. HBED has
been thoroughly characterized for iron chelation efficiencyFigure 5 The structures of previously reported and potential iron cheand toxicity. Initial studies showed that HBED is ineffect-
ive at promoting iron excretion when given orally. How-
ever, when given subcutaneously or intravenously, HBED
was more than twice as effective as DFO at mobilizing
iron from rats and cebus apella. Importantly, HBED is a
powerful antioxidant and was not associated with any
major toxicity in the models tested. Compared to DFO,
HBED showed potential as a therapeutic for treating
transfusional iron overload with the potential for dosing
every other day. HBED has been used in man but has not
been further developed for use in treating transfusional
iron overload [40].
Pyridoxal isonicotinoyl hydrazone (PIH)
Pyridoxal isonicotinoyl hydrazone (PIH) is tridentate
iron chelator (MW 287) effective at scavenging and mo-
bilizing iron (Figure 5). The potential utility of this class
of chelator, as well as its efficacy as anti-proliferative
agents, preventing free-radical mediated injury has been
documented. [41]. PIH has been shown to chelate both
forms of iron, and like other chelators it caused deple-
tion in zinc levels at physiological pH. At neutral pH,
the neutral charge of PIH ensures oral absorption and
allows access to the cytosol, where labile iron can be
chelated. PIH showed efficacy at removing iron from rat
reticulocytes which contained labile non-heme iron and
mobilizing iron from Chang cells. PIH also reduced iron
levels in major organs in mice and was tested in manlators for treating secondary iron overload.
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been reported to be toxic in cebus monkeys and although
analogues of PIH have been created none has been further
developed for use in treating iron overload in transfusion
dependent patients [41].
FBS0701
FBS0701 (SPD-602) is a novel tridentate chelator of the
desazadesferriothiocin (DADFT) class and has been tested
in phase II clinical trials (Figure 5). FBS0701 has a MW of
400 (salt form 440), binds iron tightly and has a higher
affinity for Fe(III) than other divalent metals. It can
enter cells and has demonstrated efficacy in iron chela-
tion and a comparable safety profile to currently ap-
proved chelators [42].
A one-week, dose escalation, phase Ib study demon-
strated its potential clinical utility and efficacy. While a
phase II multicenter trial, which dosed patients with 50–
375 mg of the FBS0701-salt, showed a statistical signifi-
cant reduction in liver iron, confirming the potential
benefit of this agent to reduce iron burden from transfu-
sions. Although adverse events were reported, they did
not appear to be dose related and occurred at low
frequency. Future studies with larger sample sizes will
provide more information on the potential of this chelator
for treating transfusion associated iron overload. FBS0701
is currently undergoing development and represents a
promising agent for future treatment [42].
CM1
CM1, 1-(N-Acetyl-6-Aminohexyl)-3 Hydroxy-2-Methyl-
pyridin-4-One), is an orally active, bidentate L1 analogue,
possessing a MW of 256 Da and is currently being devel-
oped for the treatment of iron overload (Figure 5). CMI
has shown higher lipophilicity than L1 and can bind both
Fe(II) and Fe(III). CM1 is effective at mobilizing cytosolic
labile iron in primary mouse hepatocytes and HepG2 cells,
and plasma NTBI. It has been studied in transgenic β-
thalassemic mice, and has demonstrated efficacy and low
toxicity in the liver and peripheral blood of iron over-
loaded mice. Importantly, CM1 showed efficacy in pre-
venting lipid peroxidation, the underlying cause of cellular
damage. Future studies are needed to determine clinical
utility of this agent [43].
Current challenges in iron chelation therapy
Monotherapy is inadequate to ensure negative iron balance
Although there are three iron chelators used for the
treatment of iron overload, often treatment with any of
these chelators alone is not sufficient and it is estimated
that 20% of patients undergoing iron chelation therapy
will be inadequately chelated [8]. This is due to factors
such as poor compliance, inefficacy and toxic side ef-
fects. For example, 80% of patients undergoing DFOtherapy will experience reactions at the infusion site; oral
DFP therapy alone will ensure a negative iron balance in
some but not all patients and DFX may cause kidney
failure in some patients.
Additionally the safety of iron chelators for certain pop-
ulations is yet to be clearly defined and remains somewhat
controversial. This is especially true for pregnant women.
Yet, the increasing lifespan of women to childbearing age
and the improvement in therapy over the last few decades
has demonstrated the increase in the likelihood and cases
of pregnancies in transfusion dependent women and the
importance to advance knowledge and treatment options
for this vulnerable group of patients.
Properties of effective iron chelators
Effective iron chelation therapy is achieved only if iron
chelators can remove equal or greater amount amounts
of iron to that accumulated due to transfusion therapy.
This requires chelators to be able to reach the target
sites at relevant concentrations. Since there are several
iron pools that develop in iron overload, chelators which
are effective at mobilizing iron from all labile iron pools
would be advantageous. Secondly, the effective protec-
tion of the heart by chelation therapy is critical for iron
overloaded patients as heart failure is the leading cause
of the death in thalassemia major patients with iron
overload [8,10].
An “ideal” chelator should have an ability to bind
NTBI over long periods of time in order to ensure ad-
equate coverage. A long acting chelator would ultimately
decrease the amount of iron that is taken up into tissues
and would prevent harmful, iron-catalyzed reactions. In
addition, iron chelators that are clinically effective must
have high selectivity for Fe(III) in comparison to other
important trace metal ions in the body. Table 1 com-
pares the features of currently available iron chelators
with that of “ideal” iron chelator features.
Overcoming the challenges in current iron chelation
therapy: the development of new polymeric iron chelators
Although all currently approved chelators are of low MW,
previous reports of polymeric iron chelators have demon-
strated that high MW chelators can be a viable alternative
for improving the pharmacokinetics and systemic toxicity
of small MW chelators (Table 2). The approach to develop
polymeric chelators or polymeric nanocarriers for iron
chelators has varied from using iron binding dendrimers,
hydrogels, the covalent attachment of DFO to a wide
range of biocompatible materials and the use of amino
acid amide derivatives. Figure 6 shows the structures of
polymeric components that have been used to modify
DFO toxicity and systemic circulation. The major motiva-
tions for producing polymeric iron chelator is to over-
come the challenges of rapid plasma elimination,
Table 1 Contrasting features of ideal and currently approved iron chelators
Chelator property Ideal chelator DFO L1 DFX
Cost Affordable for patients in low
income countries




Oral i.v injection or s.c infusion Oral Oral
Circulation t1/2 Long enough to allow once-daily
dosing and effective iron removal
Short (~20 min) requires
all-day (8-12 h) delivery
Moderate; requires at least




Therapeutic index High High at high doses in
patients with high burden
Unpredictable High








High: Long enough to prevent
drastic fluctuations in LIP
None Moderate High
Ability to remove iron
from heart, liver etc.
High Low High High
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hindered the achievement of safe iron levels in many iron
overloaded patients undergoing iron chelation therapy
Figure 7. Indeed, several studies have indicated that poly-
meric iron chelators possess unique advantages over their
low MW counterparts.
In a 1989 report, Hallaway et al. described the advan-
tages associated with attaching DFO covalently to dex-
tran and hydroxyethyl starch (HES) [44]. This resulted
in a significant increase in the plasma half-life and re-
duction in toxicity of DFO with no apparent loss in the
iron chelating properties. The increase in size of starch
conjugated DFO (S-DFO) resulted in improved plasma
half-life from 5 min for DFO to 87 min S-DFO in mice.
The LD50 in mice increased to 4000 mg/kg for dextran-
DFO in comparison to 250 mg/kg for DFO and there
was an absence of pulmonary hypotension when intra-
venously administered in dogs. This is a major improve-
ment as DFO and its iron complex induced hypotension
in dogs at a dose of 100 mg/kg. Moreover, the blood pres-
sure did not return to normal during the 60 minutes of the
experiment. In contrast, neither HES nor dextran causedTable 2 The influence of polymer conjugation on the pharma
-DFO Conjugate Pharmacodynamic effect
Dextran-DFO [44] LD50 increased from 250 mg/kg to 4000 m
reduction of pulmonary hypotension in dog
Starch-DFO (40SDO2) [47] Reduced retinal toxicity in albino rats,
Reduction of pulmonary hypotension in do
PEG-Methacrylate-DFO [46] Reduced endothelial cell toxicity
HPG-DFO [48] Increased in vivo LD50
Conjugated forms of DFO are associated with reduced toxicity both in vitro and in v
plasma half-lives than unconjugated DFO [44,46-48].any significant change in blood pressure. Additionally, the
half-life was more than 10 times greater after conjugation.
In 2005 Polomoscanik et al. reported the generation of
a non-toxic formulation of DFO hydroxamic acid based
iron chelating hydrogels and evaluated utility to prevent
iron absorption in the gut [45]. These gels were effective
in preventing gastric iron absorption and did not cause
any change in hemoglobin and hematocrit. They also
conducted a study to determine whether other divalent
metals compete with Fe(II) for binding to the polymeric
chelator and found that Zn and Cu did compete but that
overall the binding strength of the polymeric chelators
was affected only modestly. These agents prevented the
rise of hematocrit and hemoglobin in treated mice and
suggest that arresting the intestinal uptake of dietary
iron is a viable option for depleting iron levels. The
hydrophilic polymeric hydroxamic acid gel was non-
toxic and suggests the feasibility of using non-absorbed
iron binding polymers as oral agents to sequester dietary
iron in the GI tract.
In 2009, our group reported the development of well-






Increased in vivo iron excretion efficiency, increased circulation
half-life.
Excess free iron binding capacity in healthy males
–
Increased in vivo iron mobilization efficiency in mice
Increased circulation half-life in mice
Decreased clearance
ivo. Dextran-DFO, HES-DFO and HPG-DFO demonstrated significantly higher
Figure 6 The chemical structure of polymer components used in DFO modification.
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tion in iron chelation therapy [46]. PEG methacrylate
was copolymerized by the RAFT method with a func-
tional monomer for the conjugation of DFO to the poly-
mer backbone via degradable or non-degradable linkage.
The presence of PEG increased the biocompatibility of
these nanoconjugates. The presence of the hydrolysable
ester linkages was anticipated to cause slow degradation
of the conjugate via the ester linkages between the PEG
side chains and copolymer backbone. P-DFO had MWs
ranging from 27–127 kDa with between 5–26 DFO units
per polymer chain and demonstrated improved biocom-
patibility and toxicity profile as compared to unconju-
gated, small MW DFO. Like dextran and HES-DFO,
P-DFO had a drastically improved toxicity profile; while
unconjugated DFO exposure in HUVECs resulted in
death at 3 μM, P-DFO was associated with ~90% cell
viability up to 700 μM. However, to date P-DFO has not
been tested for efficacy in vivo.
The most significant evidence existing for the potential
clinical utility of polymeric iron chelators was publishedby Harmatz et al. who tested a DFO-starch conjugate
[47]. In this first reported human clinical trial of poly-
meric chelators, S-DFO caused clinically significant iron
excretion after single dose infusion of S-DFO. Maximum
plasma chelator levels of 6 mM/L were achieved by S-
DFO after 4 h intravenous infusion, an order of magni-
tude higher than that which occurs with DFO treatment.
More importantly, there was also residual iron binding
capacity present in the plasma of patients for one week,
without any observable toxicity [47].
Recently, we have achieved the longest half-life in mice
recorded to date by conjugating DFO to hyperbranched
polyglycerols (HPG) [48]. HPG is a class of versatile, bio-
compatible, inert, nano polymers that can be synthesized
in a controlled one-step reaction with low polydispersity.
Detailed biocompatibility testing of these polymers con-
ducted in vitro and in vivo has demonstrated the unique
advantages that HPG may have in nanomedicine [49,50].
Our group has previously developed HPGs as a synthetic
substitute for serum albumin that closely mimics the
binding and transport properties of natural albumin and
Figure 7 Polymeric iron chelators result in a higher unsaturated iron binding capacity (UIBC). High MW chelators have longer half-lives
and are not readily taken up by cells. In contrast, small MW chelators are highly permeable to cells and may be rapidly metabolized and removed
from the circulation.
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ally used plasma expanders [50]. We have also coated
HPG on red blood cells to mask different antigens to-
wards the development of universal blood cells, devel-
oped DNA delivery agents, and developed anticoagulant
neutralizing agents for use as heparin antidotes [51,52].
Due to the biocompatibility, multi functionality and long
circulating nature of high MW HPG, we anticipated that
it would be a promising candidate for the development
of a new generation of non-toxic macromolecular nano-
conjugates for the removal of iron in vivo.
HPG based polymeric chelators were developed by
conjugating DFO to different MW HPGs with different
DFO density, producing a library of polymeric-DFO
conjugates, referred herein as HPG-DFO. HPG-DFOconjugates varied in properties depending on their MW
and DFO density, and the structural features of HPG-
DFO were optimized to achieve long plasma circulation
time, high chelation efficiency and low toxicity. All of the
HPG-DFO conjugates demonstrated suitable biocompati-
bility and the hydrodynamic radius ranged from 4.2 to 7.9
nm. The narrow polydispersity of the polymer scaffold
allowed the development of homogeneous conjugates with
well-defined and predictable characteristics in vitro and
in vivo. The plasma circulation half-life of DFO was in-
creased more than 484-fold (44 h) for a 500 kDa conjugate
compared to that of unconjugated DFO. These conjugates
were also more efficient at mobilizing iron in mice; the
iron excretion was significantly higher in mice treated
with HPG-DFO [48]. Ongoing studies which are aimed at
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with respect to its MW and DFO density will allow further
optimization of toxicity and biodistribution.
Apart from the previously described polymeric struc-
tures with specific chelators attached to the polymer
backbone, other polymeric chelators have also been
generated. Winston et al. prepared polymeric chelators
with hydroxamic acid terminated side chains [53]. These
polymeric chelators were composed of amino acid amide
derivatives of acrylic and methacrylic acid with the ter-
minal carboxyl group converted to the hydroxamic acid.
Polymeric chelators demonstrated a high affinity for iron
(III) and were able to remove iron from iron overloaded
mice when administered via i.p. injection.
Zhou et al. reported the synthesis of 3-hydroxypyridin-
4-one hexadentate, ligand-containing copolymers by the
copolymerization of 3-hydroxypyridin-4-one hexadentate
ligand with N,N-dimethylacrylamide (DMAA), and N,N’-
ethylene-bis-acrylamide (EBAA) using (NH4)2S2O8 as the
initiator [54]. This class of chelator has demonstrated
high selectivity and affinity for iron (III), and has poten-
tial clinical utility for the treatment of iron overload
diseases associated with the hyper-absorption of iron
(e.g. hemochromatosis).
Since iron accumulates as a result of transfusions as well
as dietary absorption, it has been suggested that blocking
the intestinal absorption of iron may also significantly re-
duce iron levels in patients. This has been attempted by
administering high affinity, high MW chelators that are
not absorbed by intestinal cells, which bind iron and
promote its removal from the body. Zhou et al. designed
hydroxypyridinone-containing polymers which signifi-
cantly reduced intestinal iron uptake. In their in vitro in-
testinal perfusion study, the accumulated absorbed iron
was significantly reduced compared with the control
groups in the presence of polymeric iron chelator.
Dendrimers have also demonstrated suitability as for
the generation of polymeric iron chelators [55]. Zhou
et al. designed novel dendritic iron chelators by termin-
ating dendrimers with hexadentate ligands formed from
hydroxypyridinone, hydroxypyranone, and catechol moi-
eties and have demonstrated that these novel conjugates
can reduce iron absorption efficiently. This supports the
idea that polymeric and dendritic iron chelators may be
able to uniquely diminish iron absorption through the
intestine and may have clear potential clinical utility due
to their high MW [55].
Although the encapsulation of DFO into liposomes has
also been attempted as a means of improving the thera-
peutic index, it has been unsuccessful [56]. This is likely
because DFO encapsulation does sequesters DFO only ini-
tially, however, release profiles may not be ideal due to the
hydrophilicity and relatively large molecular weight. An-
other reason may be that if untargeted to specific tissues,DFO can still cause toxicity once released into healthy,
non-iron overloaded cells. Liposome technology and DFO
can be extremely valuable with a targeted approach to a
specific organ affected by the iron overload. It may also be
much more useful in treating cancers or tumors that have
a high iron requirement but it also has to be targeted to
ensure a very specific release location. Liposomal encapsu-
lation may also be beneficial if liposomes can be tuned to
release DFO slowly. Slow release would be beneficial and
would reduce toxicity associated with high DFO doses.
Advantages of polymeric iron chelators
There are several advantages associated with the modi-
fication of iron chelators with polymeric nanocarriers
(Table 2). One of the most important properties of an
iron chelator is its circulation half-life as this influences
the unsaturated iron binding capacity (UIBC) of the chela-
tor and ultimately, the rate of NTBI generation and re-
moval. As iron in β-TM patients is constantly being
turned over due to the RBC catabolism in macrophages or
the breakdown of ferritin within cells, these pools of iron
are redox active and are mainly responsible for the iron
loading of plasma and tissues. Thus, in order to achieve
effective iron chelation and the removal of labile iron, 24
h chelation coverage is the ideal. The importance of hav-
ing a long-circulating chelator and constant coverage has
also been demonstrated in studies that have shown that
prior to significant changes in cardiac iron in patients, car-
diac failure is reversed during continuous administration
of DFO and that NTBI appears within minutes of a chela-
tor being cleared from the body [57].
Increased half-life is anticipated to have profound effects
on compliance to therapy for patients treated with DFO.
The current arduous DFO regimen has proven chal-
lenging for many patients, especially young children and
teenagers, so an optimized version of a long circulating
DFO would be of significant benefit. If polymeric chelators
can be engineered toward slow, sustained degradation in
the plasma, it is conceivable that patients will require
once-weekly or bi-weekly injections that will enable suffi-
cient iron mobilization. In addition to improving compli-
ance, this will likely improve access to DFO for many
patients since less drug will be needed to cause effective
iron excretion and will reduce toxicities, ultimately allow-
ing a paradigm shift in chelation therapy with DFO.
Reduction in toxicity
The high MW polymeric DFO conjugates have demon-
strated efficacy at clearing excess iron in vivo with re-
duced or absent toxic effects [44-48]. The reduction in
the acute toxicity of polymer conjugated DFO as com-
pared to the parent drug, allows the administration of
much greater amounts of “active ingredient” after poly-
mer conjugation. This reduction in toxicity is most likely
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take as conjugates remain in the vascular space longer
once conjugated to polymers. It is well documented that
low MW iron chelators can be taken up by many cell
types. DFO has the highest MW among the 3 clinically ap-
proved chelators and it has the highest hydrophilicity
(with a distribution coefficient of −2) at physiological pH.
DFO enters the liver via active transport and can interact
with the LIP and facilitate the iron excretion [10].
Although a cell permeable chelator is more likely to have
access to labile cellular iron, it is not necessary for all che-
lators to have this property. In fact, in some instances it
may be disadvantageous as small chelators which are not
specific for Fe(III) or which have high affinities for Fe(II)
may chelate other essential metals, thus exerting unwanted
effects. This is well demonstrated when considering some
of the factors underlying the toxicity of low MW iron che-
lators. Low MW chelators may remove or displace essen-
tial iron or other metals. Iron chelators can interfere with
zinc, copper and other micronutrient even though the
binding affinity for these metal ions is relatively small (for
instance, the log cumulative stability constant of DFO-Fe is
30.6 versus 11.1 for DFO-Zn 2+) [18]. Zinc deficiency has
been reported in patients undergoing DFO and L1 therapy
[58]. Additionally, reducing essential iron in the cell can re-
sult in reduced cell proliferation by inhibiting intracellular
ribonucleotide reductase and cell division [59].
Polymeric iron chelators: beyond transfusional iron
overload
Iron is an essential element for several metabolic pro-
cesses and the perturbation of iron recycling and meta-
bolism has been shown to be a major factor in several
diseases. Iron removal has been shown to be a useful ap-
proach for the treatment of microbial infectious diseases,
reducing the growth rate of some cancer cells and neuro-
degenerative diseases [60-62]. Additionally, iron chelation
may be useful in malaria treatment and treatment of the
HIV virus [63,64]. Therefore, the ability to modify poly-
mers to enhance iron chelation, minimize toxicity and
maximize blood circulation may prove beneficial in de-
pleting iron stores in these disease states as well. Poly-
meric iron chelators may also be modified to enhance
targeting to specific areas of the body and may thus have
potential clinical utility beyond the treatment of iron
overload.
For example, polymeric chelators may be uniquely suited
for iron depletion at the site of tumors owing to their large
size that can be used to passively target tumors through
their compromised endothelial junctions via the enhanced
permeation and retention (EPR) effect [65]. Likewise, the
increased residence time associated with polymeric iron
chelators may have utility in treating chemotherapy pa-
tients [61]. It has been reported that cancer chemotherapyincreases the levels of NTBI due to toxicity of anticancer
drugs to bone marrow cells. This can reduce the demand
for iron by marrow cells and cause transferrin to become
fully loaded which increases NTBI and may render the
host more susceptible to oxidative damage. While low
MW chelators are prone to enter cells, high MW drugs are
almost exclusively restricted to the vascular and extracellu-
lar spaces due to the poor cellular uptake. Thus, polymeric
chelators are advantageous for such treatments.
Conclusions
Current iron chelation therapy requires the daily admin-
istration of virtually the maximum tolerated doses of
DFO, L1 and ICL-670 in order to ensure that the rates
of transfusional iron loading and iron excretion in trans-
fusion dependent patients are well matched. This result
in patients experiencing a wide range of toxicities and in
many cases, the administered doses are still insufficient
to mobilize the required amount of iron and produce
negative iron balance. As a result, chelators that are less
toxic and more efficient at iron mobilization would en-
sure rapid reduction of labile body iron and prevent the
development or progression of complications associated
with iron overload. One potentially promising approach
to advancing chelation therapy is through the use of
polymeric chelators.
The role of polymers in medical applications has seen
substantial growth over the past three decades. The use
of polymers for applications in drug delivery, for artifi-
cial organs, medical devices and dentistry is well docu-
mented. In this review we have highlighted the potential
of polymeric iron chelators for the removal of toxic iron
pools in vivo. Through appropriate design and modifica-
tion of biocompatible polymers, several high MW chela-
tors have been developed and characterized. These
conjugates take advantage of the biophysical properties
of the polymers that can extend plasma circulation and
reduce dose dependent toxicity, while retaining excellent
chelating properties. In many aspects, polymeric chela-
tors are shown to be significantly more effective than
small MW chelators at in vivo iron removal due to ex-
tended plasma circulation times and may represent a
new paradigm in treating transfusion associated iron
overload. Although none of the previously designed
polymeric chelators have advanced to the clinic, the suc-
cessful phase Ib clinical trials conducted Harmatz et al.
suggest the potential for iron removal that exists when
DFO is engineered into a high MW polymer conjugate.
Our experience with modifying the properties of low
MW iron chelators like DFO through nanoengineering
with polymers has grown only moderately from the first
attempt in 1989. It is well established that the undesirable
properties of DFO can be significantly transformed by
modification with nanomaterials, with such improvements
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To date, emphasis has been placed on modifying DFO
properties, although the possibility of engineering other
small MW iron chelators like L1 and ICL-670 to improve
their toxicity profile remains uncertain due to their bi and
tri-denticity respectively.
It is essential that polymer components are safe to use,
can be reproduced easily on large scale and are suitable
for transformation into effective pharmaceutical formu-
lations that are practical to use clinically. Therefore, fu-
ture studies must consider several important questions.
It is important to determine whether polymers such as
HPG can be further modified to generate more targeted
high MW chelators. It is also important to determine
whether the high MW chelators have specific degrad-
ation routes or are prone to accumulation with chronic
use. Since the MW of drug molecules can play a critical
role on their cellular and tissue accumulation, determin-
ing the toxicity profile of polymers and their likelihood
of reaching target sites in adequate concentrations will
be of great importance.
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